Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-014673 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-03-02 | 2023-03-01 | VIR | Sigal Charles Elliott | Dir | P - Purchase | $22.73 | +2,500 | 10.0K | +33% | +$56.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | P | A | 2,500 | $22.73 | 10,000 | I By Sigal Family Investments, LLC | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.595 to $22.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. (F3) The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |